Immune cell surface activating receptors on CD8+ T cells and NK cells

This target refers to a proprietary or unspecified group of activating receptors found on the surface of cytotoxic immune cells, including CD8+ T cells and Natural Killer (NK) cells. These receptors are essential for the recognition and destruction of abnormal cells, such as those that are virally infected or malignant (NIH, 2024). Common examples of receptors in this class include NKG2D, CD137 (4-1BB), and the natural cytotoxicity receptors (NCRs) like NKp46 (Frontiers in Immunology, 2023). In the context of drug development, these receptors are targeted by multispecific antibodies or engagers to bridge immune cells to tumor antigens, thereby bypassing traditional MHC-restricted activation (Innate Pharma, 2024). Because the specific identity of the receptor is not disclosed in the provided context, it likely represents a novel or confidential target within a pharmaceutical pipeline aimed at enhancing innate and adaptive anti-tumor immunity. Therapeutic engagement of these molecules aims to trigger the release of perforin and granzymes to induce apoptosis in target cells (PubMed, 2022).

Other names

Activating receptors on cytotoxic lymphocytesNK and CD8+ T cell activating receptorsCo-stimulatory receptors on cytotoxic cells

Engagement of these receptors by therapeutic agonists or multispecific antibodies triggers intracellular signaling (often via ITAM or DAP10/12 pathways) that activates the cytotoxic machinery of CD8+ T cells and NK cells, leading to the lysis of target cells such as tumor cells.